Voy­ager's gene ther­a­py for Parkin­son's shows promise in ear­ly da­ta from small Phase Ib tri­al

Voy­ager Ther­a­peu­tics $VY­GR re­port­ed some good news from the front lines of its gene ther­a­py clin­i­cal tri­al in Parkin­son’s, show­ing the com­pa­ny’s drug might one …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER